Piper Sandler Maintains Overweight on Day One Biopharmaceutical, Maintains $40 Price Target
Day One Biopharmaceutical Analyst Ratings
Piper Sandler Keeps Their Buy Rating on Day One Biopharmaceuticals (DAWN)
Needham Reiterates Buy on Day One Biopharmaceutical, Maintains $33 Price Target
Day One Biopharmaceutical Analyst Ratings
Analysts Are Bullish on Top Healthcare Stocks: Biomea Fusion (BMEA), Day One Biopharmaceuticals (DAWN)
Bank of America Securities Reaffirms Their Sell Rating on Day One Biopharmaceuticals (DAWN)
Analysts' Top Healthcare Picks: Viridian Therapeutics (VRDN), Day One Biopharmaceuticals (DAWN)
Buy Rating on Day One Biopharmaceuticals: Ojemda's Market Potential and Strategic Commercialization
Needham: Reiterates the Day One Biopharmaceutics (DAWN.US) rating and adjusted from buy to buy rating, target price of $33.00.
Day One Biopharmaceutical Analyst Ratings
Needham Reiterates Buy on Day One Biopharmaceutical, Maintains $33 Price Target
Analysts Offer Insights on Healthcare Companies: Day One Biopharmaceuticals (DAWN), Amgen (AMGN) and Omnicell (OMCL)
Day One Biopharmaceutical Analyst Ratings
Needham: Reiterates the Day One Biopharmaceutics (DAWN.US) rating and adjusted from buy to buy rating, target price of $33.00.
Needham Reiterates Buy on Day One Biopharmaceutical, Maintains $33 Price Target
Analysts Are Bullish on These Healthcare Stocks: Oculis Holding (OCS), Day One Biopharmaceuticals (DAWN)
Analysts Offer Insights on Healthcare Companies: Day One Biopharmaceuticals (DAWN), Biogen (BIIB) and Neurocrine (NBIX)
Needham: Maintaining the Day One Biopharmaceutics (DAWN.US) rating, adjusted from buy to buy rating, and adjusted the target price from $30.00 to $33.00.
Day One Biopharmaceutical Analyst Ratings